NVO
Novo Nordisk·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Strong Buy"
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NVO
Novo Nordisk A/S
A leading global healthcare company that develops insulin analogues, human insulin, and oral antidiabetic drugs for diabetes care
Pharmaceutical
--
07/09/1981
New York Stock Exchange
76,302
12-31
Depository Receipts (Ordinary Shares)
Novo Alle 1, DK-2880 Bagsverd, Denmark
Development and sales of diabetes medical products
Novo Nordisk A/S was established in 1989 by the merger of two Danish companies, Nordisk Gentofte A/S and Novo Industri A/S. The company is a global healthcare company and a global leader in diabetes and obesity care. The company has a broad portfolio of diabetes and obesity care and rare disease products, including glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of diabetes and obesity, modern insulin and human insulin.
Earnings Call
Q1/2025
Estimate EPS0.922941
Actual EPS0.94629
Estimate Revenue11.87B
Actual Revenue11.30B
Hims & Hers Health Q1 2025: Unraveling Contradictions in Weight Loss Guidance and GLP-1 Strategies
May 06,2025 07:34
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.930319
Actual EPS0.91
Estimate Revenue11.93B
Actual Revenue11.68B
Lexicon Pharmaceuticals’ Q2 2025: Navigating Contradictions in Trial Designs, Partnering Strategies, and Financial Guidance
Aug 06,2025 12:46
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
NVO has released its 2025 Q3 earnings. EPS was reported at 0.69, versus the expected 0.655301917996, beating expectations. The chart below visualizes how NVO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NVO has released its 2025 Q3 earnings report, with revenue of 11.79B, reflecting a YoY change of 10.56%, and net profit of 3.15B, showing a YoY change of -22.94%. The Sankey diagram below clearly presents NVO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
